Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
Artículo
![Thumbnail](/themes/Mirage2/images/cubierta.jpg)
Open/ Download
Access note
Acceso abierto
Publication date
2021Metadata
Show full item record
Cómo citar
Renner, Alex
Cómo citar
Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
Author
Abstract
Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown
activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI
agents in the first- and second-line settings. This has led to an increased interest in studying
their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant
unmet need. This non-systematic review will look at the evidence supporting the use of ICI
in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and
possible future applications for these drugs.
Indexation
Artículo de publícación WoS
Quote Item
Ther Adv Urol 2021, Vol. 13: 1–7
Collections
The following license files are associated with this item: